DR. MATTHEW D MCLEOD, MD
Radiology at Parkman St, Boston, MA

2008017, Jul 24, 2008

Aug 20, 2007

11/894261

Martin Williams - Cambridge MA, US
Matthew McLeod - Boston MA, US
Keizo Koya - Chestnut Hill MA, US

A61K 31/397, A61K 31/165, A61P 35/00

51421006, 514599

Disclosed herein are methods of preventing or delaying the recurrence of melanoma in a subject with bis(thio-hydrazide amides) represented by a formula selected from Structural Formulas (I)-(IX) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.

2008022, Sep 18, 2008

Aug 20, 2007

11/894270

Matthew McLeod - Boston MA, US

A61K 31/165, A61K 31/337, A61K 33/24, A61K 31/655, A61K 38/21, A61K 38/20, A61K 31/4188, A61K 31/662, A61K 31/4412, A61P 35/00

424 852, 514599, 514449, 424649, 514151, 424 854, 514393, 514119, 514350

Disclosed herein are methods of treating lentigo maligna, superficial spreading malignant melanoma, acral lentiginous malignant melanoma or nodular malignant melanoma with bis(thio-hydrazide amides) represented by a formula selected from structural formulas (i)-(ix) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.

8017654, Sep 13, 2011

Apr 13, 2006

11/918357

Thomas A. Dahl - Cambridge MA, US
Matthew McLeod - Boston MA, US

Synta Pharmaceuticals Corp. - Lexington MA

A01N 37/18, A61K 31/16, C07D 305/00, C07D 407/00, C07D 493/00, C07C 241/00, C07C 243/00, C07C 249/00, C07C 251/00

514615, 549510, 564149

A method of treating a subject with cancer includes the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2 (e. g. , equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between about 1473 μmol/m2 and about 1722 μmol/m2 (e. g. , Compound (1) in about 590-690 mg/m2). The bis(thiohydrazide amide) is represented by Structural Formula (I), Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R-Rare independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, and/or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R-Rare independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.

2012023, Sep 13, 2012

Sep 12, 2011

13/230315

Thomas A. Dahl - Cambridge MA, US
Matthew McLeod - Boston MA, US

Synta Pharmaceuticals Corp. - Lexington MA

A61K 31/337, A61P 35/00

514449

Disclosed is a method of treating a subject with cancer, the method comprising the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/mto 315 μmol/m; and a bis(thiohydrazide amide) compound in an amount between about 1473 μmol/mand about 1722 μmol/m.